NCT06207123 2026-03-18
A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
University of Chicago
Phase 1/2 Recruiting
Clinical Trials
35 trialsNCT04663347 2026-03-03
EPCOREâ„¢ NHL-2
Genmab
Phase 1/2 Active not recruiting
NCT07387926 2026-02-04
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
Novartis
Phase 1/2 Not yet recruiting
NCT05848687 2026-01-13
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
Stanford University
Phase 1/2 Recruiting
NCT03808610 2026-01-09
Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT04068597 2025-12-18
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
CellCentric Ltd.
Phase 1/2 Recruiting
NCT02553460 2025-12-10
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
St. Jude Children's Research Hospital
Phase 1/2 Active not recruiting
NCT05192889 2025-09-22
Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
St. Jude Children's Research Hospital
Phase 1/2 Active not recruiting
NCT05658640 2025-09-16
HEM-iSMART D
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Recruiting
NCT05745714 2025-09-16
HEM-iSMART C
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Recruiting
NCT05751044 2025-09-16
HEM-iSMART B
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Recruiting
NCT05032183 2025-08-11
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT03817320 2025-06-17
PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1/2 Active not recruiting
NCT04752163 2025-05-23
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT03576547 2025-05-08
Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT06376721 2024-04-19
Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma
Beijing Tongren Hospital
Phase 1/2 Recruiting
NCT03705507 2023-05-11
SeluDex
University of Birmingham
Phase 1/2 Terminated
NCT03467256 2023-02-24
CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 1/2 Unknown
NCT05441761 2022-07-01
Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL
Peking Union Medical College Hospital
Phase 1/2 Unknown
NCT00061945 2022-05-03
Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00477412 2022-01-28
Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT04882163 2021-10-05
Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
Celgene
Phase 1/2 Withdrawn
NCT01381692 2021-10-04
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00299182 2021-09-21
Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03892421 2021-05-18
Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin Lymphoma
La Raza Medical Center
Phase 1/2 Completed
NCT00439296 2021-03-17
ABT-751 With Chemotherapy for Relapsed Pediatric ALL
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1/2 Terminated
NCT01483690 2020-10-27
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1/2 Terminated
NCT01983969 2020-01-27
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02404220 2020-01-02
Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Gilead Sciences
Phase 1/2 Terminated
NCT02589145 2019-12-13
Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT00144963 2019-12-12
Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Acrotech Biopharma Inc.
Phase 1/2 Completed
NCT02518113 2019-09-11
A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL
Eli Lilly and Company
Phase 1/2 Completed
NCT02983097 2018-01-19
R²-DHAP
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Phase 1/2 Terminated
NCT00531284 2017-08-15
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Amgen
Phase 1/2 Completed
NCT00776802 2013-06-25
GCS-100LE
La Jolla Pharmaceutical Company
Phase 1/2 Withdrawn